4-(1-(3-(hydroxymethyl)-2-methylphenyl )ethyl)-1H-imidazole-2(3H)-thione

Details for Australian Patent Application No. 2010213649 (hide)

Owner Allergan, Inc.

Inventors Gil, Daniel W.

Agent Davies Collison Cave

Pub. Number AU-A-2010213649

PCT Pub. Number WO2010/093910

Priority 61/152,487 13.02.09 US

Filing date 12 February 2010

Wipo publication date 19 August 2010

International Classifications

C07D 233/84 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

A61K 31/4164 (2006.01) - 1,3-Diazoles

A61P 25/04 (2006.01) Drugs for disorders of the nervous system

Event Publications

8 September 2011 PCT application entered the National Phase

  PCT publication WO2010/093910 Priority application(s): WO2010/093910

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010213656-Saccharifying biomass

2010213635-Multiple seismic signal inversion